Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
13F holders, Q3 2021
Institutional positions in Gain Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- 0 vs. Q2 2021
- Shares held
- 892.6K
- −1.67K (−0.2%) vs. Q2 2021
- Total value
- $6.65M
- −$2.30M (−25.7%) vs. Q2 2021
- New holders
- 2
- 4 more added
- Sold out
- 2
- 2 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GANX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 50 | $17.4M |
| Q1 2026 | 42 | $15.8M |
| Q4 2025 | 48 | $25.9M |
| Q3 2025 | 38 | $7.70M |
| Q2 2025 | 35 | $6.49M |
| Q1 2025 | 33 | $5.07M |
| Q4 2024 | 25 | $3.94M |
| Q3 2024 | 19 | $2.40M |
| Q2 2024 | 28 | $3.89M |
| Q1 2024 | 26 | $7.04M |
| Q4 2023 | 24 | $5.05M |
| Q3 2023 | 24 | $4.95M |
| Q2 2023 | 24 | $5.68M |
| Q1 2023 | 22 | $5.54M |
| Q4 2022 | 21 | $3.78M |
| Q3 2022 | 23 | $3.95M |
| Q2 2022 | 16 | $3.87M |
| Q1 2022 | 16 | $4.75M |
| Q4 2021 | 19 | $5.71M |
| Q3 2021 | 14 | $6.65M |
| Q2 2021 | 14 | $8.95M |
| Q1 2021 | 12 | $15.0M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Gain Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Greenlight Capital Inc | 546,560 | $4.07M | 0.27% | 00.0% | Unchanged |
| Telemetry Investments, L.L.C. | 96,232 | $716.0K | 0.98% | +65,939+217.7% | Added |
| CM Management, LLC | 64,327 | $479.0K | 0.36% | +54,327+543.3% | Added |
| Prelude Capital Management, LLC | 58,100 | $433.0K | 0.02% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 50,000 | $372.0K | 0.01% | 00.0% | Unchanged |
| Indie Asset Partners, LLC | 29,652 | $221.0K | 0.18% | +29,652 | New |
| Veritable, L.P. | 25,064 | $187.0K | 0.00% | +25,064 | New |
| BlackRock Inc. | 11,476 | $85.0K | 0.00% | −183−1.6% | Reduced |
| UBS Group AG | 6,740 | $51.0K | 0.00% | +2,640+64.4% | Added |
| Banque Cantonale Vaudoise | 3,000 | $22.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 800 | $6.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 555 | $4.00K | 0.00% | +483+670.8% | Added |
| Steward Partners Investment Advisory, LLC | 100 | $1.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 23 | $0 | 0.00% | −1−4.2% | Reduced |
| Granite Point Capital Management, L.P. | 0 | $0 | 0.00% | −155,709−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −23,878−100.0% | Sold out |